Form 4: Guardant Health CTO Executes RSU Vesting Transaction

Guardant Health Chief Technology Officer Darya Chudova acquired 8,705 shares via RSU vesting, with 4,679 shares withheld for taxes.

Summary

• Darya Chudova, Chief Technology Officer of Guardant Health, Inc., exercised restricted stock units (RSUs) on May 15, 2026.
• A total of 8,705 shares were acquired upon the vesting of an RSU award granted on August 7, 2023.
• The company withheld 4,679 shares at a price of $94.92 per share to satisfy tax withholding obligations.
• Following these transactions, the reporting person holds 74,402 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents standard executive compensation vesting rather than a discretionary market trade.

Positives

• The transaction reflects the ongoing vesting of equity compensation, aligning the interests of the CTO with long-term shareholder value.

Negatives

• The company withheld 4,679 shares to cover tax liabilities, which is a standard administrative procedure but reduces the net shares added to the insider's holdings.

Risks

• No specific operational or financial risks were disclosed in this regulatory filing.

Future Outlook

The RSU award vests over a four-year period, with the remaining 75% of the original grant vesting annually over the next three years.

Management Comments

• The filing notes that the amount of shares retained by the company for tax purposes was not in excess of the actual tax liability.

Industry Context

StockSavvy.ai notes that this is a routine insider transaction related to equity compensation plans, common among high-growth biotech firms like Guardant Health to retain key executive talent.

Comparison to Industry Standards

• The use of RSU vesting and net-settlement for tax obligations is standard practice for executive compensation in the biotechnology and life sciences sectors.
• The vesting schedule of four years is consistent with industry norms for retaining senior leadership.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine equity compensation event.

Next Steps

• Continued annual vesting of the remaining 75% of the RSU award over the next three years.

Key Dates

Keywords

Guardant Health, GH, Form 4, Insider Trading, Equity Compensation, Restricted Stock Units, Darya Chudova